CONTINUING MEDICAL EDUCATION
Imedex, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This activity has been approved for 14.00 of AMA PRA Category 1 credits™.

 

WHO SHOULD ATTEND?
This meeting is intended for urologists, medical oncologists, radiation oncologists, surgeons and other healthcare providers involved or interested in management of renal, bladder and prostate cancer.

 

OBJECTIVES
After successful completion of this continuing medical education activity, participants should be able to:
-Comment on current trends to improve the diagnosis and prognosis of renal, bladder, and prostate cancers
-Recommend treatment modalities and emerging therapeutic approaches based on assimilation of expert-guided case presentations
-Implement state-of-the-art surgical advancements in renal, bladder and prostate cancers
-Improve patient stratification for front-line use of systemic therapies in metastatic and advanced renal cell carcinomas
-Stratify patients according to eligibility for open or laparoscopic partial nephrectomy
-Determine clinical approach for patients non-responsive to sunitinib treatment in advanced renal cell carcinoma
-Minimize toxicities associated with the use of targeted therapies in the treatment of metastatic or advanced disease in renal cell carcinoma
-Compare and contrast systemic therapy regimens for hormone-sensitive and hormone-refractory prostate cancer
-Highlight recent advances in targeting the androgen receptor axis to improve treatment modalities in prostate cancer
-Employ the optimal type and timing of radiation therapy in localized prostate cancer
-Discuss the role of androgen deprivation therapy in patients with prostate cancer
-Implement strategies to manage erectile dysfunction following prostate cancer treatment
-Implement bone-sparing agents into clinical practice to prevent or minimize the toxicities experienced in patients on hormonal therapy regimens 
-Recommend the most effective therapeutic approaches for patients with non-invasive bladder cancer
-Integrate adjuvant and neoadjuvant therapeutic strategies to improve upon current patient outcomes in locally advanced bladder cancer
-Select the most appropriate clinical approach to treat locally advanced and metastatic bladder cancer in terms of  transurethral resection, cystectomy, and systemic therapy
-Review the role of intravesical chemotherapy in bladder cancer and recommend the most favorable agent

 

Vincent Bird, MD University of Miami Miami, Florida Steven C. Campbell, MD, PhD Cleveland Clinic Cleveland, Ohio Robert Dreicer, MD, FACP Taussig Cancer Institute Cleveland Clinic Cleveland, Ohio Drogo Montague, MD Cleveland Clinic Cleveland, Ohio

William Oh, MD Dana-Farber Cancer Institute Boston, Massachusetts Alan Pollack, MD, PhD Fox Chase Cancer Center Philadelphia, Pennsylvania William See, MD Medical College of Wisconsin Milwaukee, Wisconsin

Mark S. Soloway, MD University of Miami School of Medicine Miami, Florida Walter M. Stadler, MD The University of Chicago Medical Center Chicago, Illinois Gary D. Steinberg, MD, FACS University of Chicago Chicago, Illinois

 

Friday, September 5, 2008

8:00 am
Welcome and introduction
Mark S. Soloway, MD
Robert Dreicer, MD, FACP

Prostate cancer
Session I: Clinical T1-T2 prostate cancer

8:10 am           
Active surveillance: Best criteria, candidates, and triggers for active therapy
Laurence H. Klotz, MD
                                 
8:30 am
Radiation as the primary treatment for localized disease
Alan Pollack, MD, PhD

8:50 am
Management of erectile dysfunction and other quality-of-life issues following local treatment of prostate cancer
Drogo Montague, MD

9:10 am
Discussion

9:20 am
Coffee break

Session II: Case discussions: Management of T1-T2 prostate cancer:
Selection and integration of multiple treatment regimens
Moderators: Mark S. Soloway, MD and Robert Dreicer, MD, FACP
                      
Panel:
Laurence H. Klotz, MD
Drogo Montague, MD
Alan Pollack, MD, PhD
William See, MD

Cases:         

• Low risk prostate cancer
• T2, Gleason 7 prostate cancer: The role of androgen deprivation therapy
• The role of radiation therapy
• How to decide on most appropriate type of radiotherapeutic therapy (external beam radiation, intensity modulated radiation therapy, brachytherapy, and proton therapy)
• Should all men with adverse risk factors for prostate cancer take 5-alpha reductase inhibitors?

           
11:30 am
Lunch break

Session III: Systemic therapy for high-risk and advanced prostate cancer
Moderator: Mark S. Soloway, MD

12:30 pm
Patterns of toxicities including bone mineral density loss with androgen-deprivation therapy
Robert Dreicer, MD, FACP

12:50 pm
Advances in systemic therapy for hormone refractory prostate cancer
William Oh, MD  

1:10 pm
Targeting the androgen receptor axis in prostate cancer
William Oh, MD

1:30 pm
Discussion  

1:40 pm           
Coffee break

Session IV: Case discussions: Current concepts in the management of high-risk prostate cancer
Moderators: Robert Dreicer, MD, FACP & Mark S. Soloway, MD
                       
Panel:
Laurence H. Klotz, MD
William Oh, MD
Alan Pollack, MD, PhD
William See, MD

Cases:

• Role of second line androgen deprivation therapy
• Role of chemotherapy in asymptomatic patients with advanced disease
• Timing of therapy for node-positive patients
• Management of the post-docetaxel patient

Session V: Translational science: Integrating advances on the horizon in urologic oncology
           
3:30 pm
How will molecular biology improve future care of patients with genitourinary tumors?
Carlos Cordon-Cardo, MD, PhD

4:00 pm
Discussion
           
4:15 pm
Adjourn

 

Saturday, September 6, 2008

8:00 am
Welcome and introduction

Bladder cancer
Session VI: Bladder cancer
Moderator: Mark S. Soloway, MD

8:00 am
EAU, AUA and SIU guidelines for Ta-T1 bladder cancers, do we all agree?
Mark S. Soloway, MD

8:20 am
Decision processes on T1 bladder cancer: When bladder preservation should and should not be considered
Dr. Gary D. Steinberg, MD, FACS

8:40 am           
Advances in systemic therapy for urothelial carcinoma
Robert Driecer, MD, FACP

9:00 am
Discussion  
           
Session VII: Case discussions: Therapeutic decision making in bladder cancer
Moderators: Mark S. Soloway, MD and Robert Dreicer, MD, FACP
                               
Panel:
Steven C. Campbell, MD,
Gary D. Steinberg, MD, FACS

Cases:         

• Intravesical therapy: Which agent for which patient?
• Importance of repeat TURBT
• Neoadjuvant versus adjuvant chemotherapy for locally advanced bladder cancer- is there a standard?
• Emerging options in metastatic bladder cancer
• What is the role of bladder cancer preservation for T2 bladder cancer?
• Maintenance BCG: which patients and for how long?

10:40 am
Coffee break

Renal cancer
Session VIII: Novel approaches to the management of local and locally advanced renal cell cancer
Moderator: Robert Dreicer, MD, FACP

11:00 am
Management of small renal masses
Vincent Bird, MD

11:20 am
Technical aspects and indications for partial nephrectomy: How do I choose between open and laparoscopic approaches?
Steven C. Campbell, MD, PhD

11:40 am
Discussion  

11:50 am
Lunch break
           
Session IX: Case discussions: Controversies in modern management approaches
Moderators: Mark S. Soloway, MD and Robert Dreicer, MD, FACP
                           
12:50 pm
Panel:
Vincent Bird, MD
Steven C. Campbell, MD, PhD
Walter M. Stadler, MD

Cases:

• Role of adjuvant therapy
• T3 patient with vena cava involvement
• Role of systemic therapy for high risk clinically localized renal cancer
• Integrating systemic therapy in advanced disease and the role of cytoreduction  
  

Session X: Systemic therapies for metastatic renal cell carcinomas
Moderator: Robert Dreicer, MD, FACP

2:20 pm
Optimal sequencing and combining of systemic therapies for metastatic disease
Robert Dreicer, MD, FACP

3:40 pm
Novel emerging therapies for renal cell carcinoma
Walter M. Stadler, MD

3:00 pm
Discussion  

Session XI: Case discussions: Recent advances for metastatic and advanced renal cell
carcinoma

3:10 pm
Panel:
Steven C. Campbell, MD, PhD
Robert Creicer, MD, FACP
Walter M. Stadler, MD
                               
Cases:

• Choosing initial systemic therapy for metastatic disease
• Management options for patients who have failed sunitinib            
• Therapeutic options in patients with non-clear cell histology
• Managing adverse event profiles of novel targeted agents                     

4:40 pm
Adjourn

REGISTRATION FEES
Regular . . . . . . . . . . . . . . . . . . . . . $345
If payment received after August 28, 2008

Full/Onsite . . . . . . . . . . . . . . . . . . . $445
To register after August 28, 2008

Nurses, Fellows, Resident . . . . . . . . . $99
*proof of eligibility must accompany registration

Group discount (physicians only)* . . . . -$50
*cannot be combined with any other discounts

To Register
You may register online by August 28, 2008 or by calling Imedex at +1 (678) 242 0906. Registration confirmations will be issued before the meeting.

To qualify for special registration fees, registration and full payment must be received by Imedex by the dates specified Group Discounts Each one of multiple registrants from the same institute or practice each receive a $50 discount off the published registration fees, provided all registration forms and payments are received together. Only one discount will apply per physician. Group discounts are not available for nurses, residentsm or students.

Payment
To pre-register, registration and payment must be received no later than August 28, 2008. Please register onsite after this date. Contact Imedex at +1 (678) 242 0906 or visit our website at www.imedex.com to ensure the course is being held as scheduled and to confirm that the meeting is not full. Registration fees must be remitted by credit card or check. Checks should be payable to Imedex. Include the full name of the attendee and the name of the conference: Perspectives in Urologic Oncology & A039.01. An attendee is not registered until full payment is received.

Registration Fee Inclusions
Registration fees include admittance to all scientific sessions, conference materials, processing of certificates of attendance or continuing medical education, and all event functions as specified in this announcement.

Cancellation
For registration fees to be refunded, written notice of cancellation must be received at meetings@imedex.com no later than August 28, 2008. The amount of registration fees remitted, minus a $75 administrative charge, will be refunded after the conference. Substitutions are accepted with written notification. No refunds will be made if notice is received after August 28, 2008. Imedex does not accept responsibility for covering travel, accommodation or any other costs incurred by registrants in the rare event that this meeting should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation. The event agenda is subject to change without notice.

Wyndham Chicago
633 North St. Clair Street
Chicago, Illinois 60611
Tel.: +1 (312) 573 0300
Fax: +1 (312) 274 0164

The Wyndham Chicago is an oasis of comfort and style in the heart of Chicago’s Magnificent Mile. Just one block off Michigan Avenue in a neighborhood full of world-class restaurants, shopping, museums and galleries. Lake Michigan, the Symphony Center and the Loop financial district are all nearby.

Settle into a spacious room or suite with a dazzling view of downtown Chicago. Enjoy thoughtful touches like high-speed Internet access and a cordless multi-line phone. Dine at the chic Caliterra Bar & Grille or unwind in the fitness center and indoor pool. Relax with a walk through the vibrant neighborhood - or let the concierge plan a special outing.

For the convenience of attendees, a limited number of rooms have been reserved until August 5, 2008 at a discounted rate of $229 single/double occupancy, plus tax, currently at 15.4%. This rate is not guaranteed outside the conference dates or after August 5, 2008.

To reserve your room please contact the Wyndham Chicago reservations department at +1 (312) 573 0300. To receive the group rate, callers must identify themselves as being with the Perspectives in Urologic Oncology group. Reservation requests received after August 5, 2008 may not be guaranteed the group rate.

 

CHAIRS
Robert Dreicer, MD, FACP
Taussig Cancer Institute
Cleveland Clinic
Cleveland, Ohio

Mark S. Soloway, MD
University of Miami School of Medicine
Miami, Florida

INVITATION
It is with great pleasure that we invite you to attend the 2nd Annual Perspectives in Urologic Oncology: A Case-Based Conference to Enhance Patient Management of Prostate, Renal and Bladder Cancer to be held September 5-6, 2008 in Chicago, Illinois. This conference will be a forum where urologists and medical/radiation oncologists can come together to learn and share their clinical experiences through both lecture presentations and interactive case discussions. Our panel of world-renowned experts will touch on the most significant aspects of prostate, renal, and bladder cancers. We will discuss the status of the latest treatment modalities as well as emerging approaches to therapy. The meeting will delve into the areas of controversy through vigorous discussion and debate using information from clinical trials as applicable. The speakers have all been selected because of their strong therapy area experience and ability to communicate effectively. Our ultimate goal is to provide you with the information needed to optimize patient care and to make you aware of pertinent current trends and evolutions. We hope you will join us in Chicago for what is sure to be an outstanding event with many lively discussions! Sincerely, Robert Dreicer, MD, FACP and Mark S. Soloway, MD

CONFERENCE LOCATION
Wyndham Chicago
633 North St. Clair Street
Chicago, Illinois 60611
Tel.: +1 (312) 573 0300
Fax: +1 (312) 274 0164

The Registration and Information Desk will be staffed:
Friday, September 5, 2008 . . . . . . . . . 7:00 am – 4:30 pm
Saturday, September 6, 2008 . . . . . . . 7:30 am – 4:00 pm

Discounted Airfares Contact conference travel agent, Judi Tarpley with Williamsburg Travel, for assistance with your travel needs. Williamsburg Travel can also accommodate pre- and post-conference extensions. Tel.: +1 (888) 232 9394 or +1 (770) 261 8613

 

ORGANIZER
Imedex
4325 Alexander Drive
Alpharetta, GA 30022-3740 USA
Tel.: +1 (770) 751 7332
Fax: +1 (770) 751 7334
Email: meetings@imedex.com
Web: www.imedex.com

 

Imedex is a brand and assumed name used by Imedex, LLC (hereby referred to as Imedex). Imedex is solely responsible for this agenda’s content. Although Imedex attempts to ensure that the information in our program is accurate and timely, matters and opinions discussed and/or presented with respect to clinical matters are those of the discussion participants only, and not necessarily those of Imedex. Moreover, although Imedex attempts to identify and integrate the most qualified medical professionals in our program, TO THE FULLEST EXTENT PERMITTED BY LAW, IMEDEX EXPRESSLY DISCLAIM ALL WARRANTIES, EITHER EXPRESS OR IMPLIED, STATUTORY OR OTHERWISE, INCLUDING BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY, NON-INFRINGEMENT OF THIRD PARTIES’ RIGHTS, AND FITNESS FOR A PARTICULAR PURPOSE, WITH RESPECT TO THE CONTENT PRESENTED. IMEDEX FURTHER MAKES NO REPRESENTATIONS OR WARRANTIES ABOUT THE ACCURACY, RELIABILITY, COMPLETENESS OR TIMELINESS OF THE CONTENT OR ANY MATERIAL PRESENTED.

In addition, the material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual’s own physician.

Neither Imedex nor any of its subsidiaries or affiliates is affiliated with or formally endorsed by a medical society.

©2008 Imedex^®, LLC. All rights reserved.
Reproduction in whole or part is prohibited without prior written consent from Imedex and contributing faculty.

CORPORATE SUPPORT
The following companies have provided an unrestricted educational grant in support of this conference:

Platinum   Silver Genentech BioOncology   Corporate   Exhibitor

 

Several options are available to companies interested in supporting this congress. For more information, please contact Imedex at +1 (770) 751 7332 or by email at CME@imedex.com.